paconan
Será en Octubre
- Desde
- 5 Ago 2008
- Mensajes
- 29.595
- Reputación
- 119.489
Y con esos datos pretenden obligar o convencer al personal para que se vacune? es una broma ,no?Mirad con que han aprobado la banderilla de Pfizer (la UE):
Comirnaty - European Medicines Agency
The study showed a 95% reduction in the number of symptomatic el bichito-19 cases in the people who received the vaccine (8 cases out of 18,198 got el bichito-19 symptoms) compared with people who received a dummy injection (162 cases out of 18,325 got el bichito-19 symptoms). This means that the vaccine demonstrated a 95% efficacy in the trial.
No saben cuantos han cogido el bichito con la banderilla, solo que reduce los sintomas.
There were not enough data from the trial to conclude on how well Comirnaty works for people who have already had el bichito-19.
No saben que pasa si la gente ya ha tenido el bichito y le inyectas la banderilla.
The impact of vaccination with Comirnaty on the spread of the SARS-CoV-2 bichito in the community is not yet known. It is not yet known how much vaccinated people may still be able to carry and spread the bichito.
No saben si pueden o no pueden contagiar.
It is not currently known how long protection given by Comirnaty lasts.
No saben cuanto dura la protección.
Comirnaty is not currently recommended for children below 16 years of age. EMA has agreed with the company on a plan to trial the vaccine in children at a later stage.
Mejor no se la damos a los niños.
There are limited data on immunocompromised people (people with weakened immune systems). Although immunocompromised people may not respond as well to the vaccine, there are no particular safety concerns. Immunocompromised people can still be vaccinated as they may be at higher risk from el bichito-19.
No sabemos que pasa con los que tienen el sistema inmune debil (pueden responder mal).
Animal studies do not show any harmful effects in pregnancy, however data on the use of Comirnaty during pregnancy are very limited. Although there are no studies on breast-feeding, no risk for breast-feeding is expected.
The decision on whether to use the vaccine in pregnant women should be made in close consultation with a healthcare professional after considering the benefits and risks.
En cuanto a embarazadas han hecho pruebas en animales (pero pocas) y no esperan riesgo en la lactancia (pero no han hecho estudios). Pero no quieren tomar la decision, que la tome el médico.
Allergic reactions (hypersensitivity) have been seen in people receiving the vaccine. A very small number of cases of anaphylaxis (severe allergic reaction) have occurred since the vaccine started being used in vaccination campaigns. Therefore, as for all vaccines, Comirnaty should be given under close medical supervision, with the appropriate medical treatment available. People who have a severe allergic reaction when they are given the first dose of Comirnaty should not receive the second dose.
Puede haber reacciones alergicas (no nos dan la cifra aunque dicen que son muy pocas. Yo esperaria de la EMA una cifra).
The most common side effects with Comirnaty in the trial were usually mild or moderate and got better within a few days after vaccination. These included pain and swelling at the injection site, tiredness, headache, muscle and joint pain, chills and fever. They affected more than 1 in 10 people.
Redness at the injection site and nausea occurred in less than 1 in 10 people. Itching at the injection site, pain in the limb, enlarged lymph nodes, difficulty sleeping and feeling unwell were uncommon side effects (affecting less than 1 in 100 people). Weakness in muscles on one side of face (acute peripheral facial paralysis or palsy) occurred rarely in less than 1 in 1,000 people.
Allergic reactions have occurred with Comirnaty, including a very small number of cases of severe allergic reactions (anaphylaxis) which have occurred when Comirnaty has been used in vaccination campaigns. As for all vaccines, Comirnaty should be given under close supervision with appropriate medical treatment available.
También me hubiera gustado mas precisión por parte de la EMA con un porcentaje de cada caso. (no es lo mismo 1,2 que 9,5 y ambos son uno de cada 10)
Sería bueno saber cuantos se han muerto (porque si no se ha muerto ninguno, hay más en el grupo de la banderilla que han tenido sintomas que en el grupo del placebo.
Con razón no se la pone el ceo de pfizer...